Autonomix Medical activates a $1.35M ATM program, risking 30% dilution

summarizeSummary

Autonomix Medical filed a prospectus supplement to sell up to $1.35 million of common stock through an at-the-market program, potentially diluting existing shareholders by about 30%.

check_boxKey Events · Financing and Capital Events · AMIX

• ATM Program Activated

  The company may sell up to $1.35 million of common stock from time to time through Ladenburg Thalmann, with a 3.0% commission on gross proceeds.

• Potential 30% Dilution

  At an assumed price of $4.57 per share, the offering could add 295,404 shares, increasing the outstanding count from 971,043 to approximately 1.27 million shares.

• Near-Term Cash Need

  With a going concern warning and a market cap of only $3.3 million, the ATM provides critical working capital but dilutes existing holders significantly.

• Shelf Capacity Nearly Exhausted

  The company has already sold $1.4 million of securities under the S-3 shelf in the prior 12 months, approaching the one-third public float limit of approximately $2.8 million.

auto_awesomeAnalysis · AMIX · Industrial Applications And Services

Autonomix Medical has activated an at-the-market (ATM) program to sell up to $1.35 million of common stock. At an assumed price of $4.57, this could add 295,404 shares—roughly 30% dilution to the current 971,043 shares outstanding. The company is burning cash with a going concern warning and a market cap of only $3.3 million, so this ATM provides a lifeline but at a steep cost to existing shareholders. The filing also reveals that $1.4 million of securities have already been sold under the shelf in the past year, nearing the one-third public float limit, which may constrain future raises.